Brokerages Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Price Target at $5.17

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has received an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $5.17.

Several equities research analysts have recently weighed in on the stock. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $2.00 price target on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th. Truist Financial decreased their price objective on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Monday, April 7th.

Sangamo Therapeutics Stock Performance

Shares of NASDAQ:SGMO opened at $0.70 on Monday. The firm’s 50 day simple moving average is $0.78 and its 200-day simple moving average is $1.36. Sangamo Therapeutics has a one year low of $0.30 and a one year high of $3.18. The firm has a market cap of $160.44 million, a PE ratio of -0.93 and a beta of 1.46.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). The firm had revenue of $7.55 million for the quarter, compared to the consensus estimate of $11.70 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. Equities research analysts predict that Sangamo Therapeutics will post -0.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. E Fund Management Co. Ltd. purchased a new stake in shares of Sangamo Therapeutics during the fourth quarter valued at $25,000. JPMorgan Chase & Co. lifted its holdings in shares of Sangamo Therapeutics by 679.5% during the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 21,793 shares during the period. PNC Financial Services Group Inc. boosted its position in Sangamo Therapeutics by 2,319.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 25,000 shares during the last quarter. SBI Securities Co. Ltd. acquired a new position in Sangamo Therapeutics in the 4th quarter worth approximately $28,000. Finally, Shelton Wealth Management LLC purchased a new position in Sangamo Therapeutics during the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.